Clinical Chemistry Link to Randox Laboratories Web Site
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Clinical Chemistry 31: 2014-2017, 1985;
This Article
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Beinlich, C. J.
Right arrow Articles by White, O. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Beinlich, C. J.
Right arrow Articles by White, O. D.

Clinical Chemistry, Vol 31, 2014-2017, Copyright © 1985 by American Association for Clinical Chemistry

Evaluation of dual-label simultaneous assays for lutropin and follitropin in serum

CJ Beinlich, JA Piper, JC O'Neal and OD White

We evaluated the analytical performance and clinical utility of three dual-label simultaneous assays for lutropin and follitropin by comparison with widely used individual assays for these analytes (Diagnostic Products Corp.; DPC). Of the three assays evaluated, "Cotropin" (Clinetics Corp.) and "Combostat" (Micromedics Systems, Inc.) compared favorably with the DPC assay with respect to recovery, linearity, intra- and inter-assay precision, and sensitivity for lutropin. The third assay evaluated, "Simultropin" (Becton Dickinson Immunodiagnostics), exhibited greater interassay variability for lutropin than did the DPC assay but otherwise compared favorably. Analytically the three assays were similar to one another for follitropin determinations and results compared favorably with those by the DPC assay. Intercorrelation of patients' results obtained with these assays is poor. However, using the same standards with each of the three assays improved intercorrelation of patients' data except for follitropin by Combostat. A universally accepted reference material for immunoassay of lutropin and follitropin is needed.




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1985 by the American Association for Clinical Chemistry.